H4512
氢氯噻嗪
drug standard, 1.0 mg/mL in methanol
别名:
6-氯-3,4-二氢-2H-1,2,4-苯并噻二嗪-7-磺酰胺1,1-二氧化物, 6-氯-7-磺酰胺-3,4-二氢-1,2,4-苯并噻二嗪-1,1-二氧化物
等级
drug standard
方案
≥98%
浓度
1.0 mg/mL in methanol
技术
HPLC: suitable
gas chromatography (GC): suitable
包装形式
single component solution
储存温度
2-8°C
SMILES字符串
NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl
InChI
1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)
InChI key
JZUFKLXOESDKRF-UHFFFAOYSA-N
基因信息
human ... CA1(759), CA4(762), SLC12A3(6559)
正在寻找类似产品? 访问 产品对比指南
应用
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
生化/生理作用
碳酸酐酶抑制剂
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - STOT SE 1
靶器官
Eyes,Central nervous system
储存分类代码
3 - Flammable liquids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
法规信息
新产品
此项目有
Johannes A N Dorresteijn et al.
Journal of hypertension, 31(2), 393-403 (2012-12-14)
The objective of this study is to determine the effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension. A randomized, four-way, double-blind, crossover study in 31 adults with previously untreated obesity-related
Biopharmaceutical studies of thiazide diuretics. II. High-performance liquid chromatographic method for determination of hydrochlorothiazide in plasma, urine, blood cells and bile.
M Yamazaki et al.
Chemical & pharmaceutical bulletin, 32(6), 2387-2394 (1984-06-01)
A Dornhorst et al.
Lancet (London, England), 1(8421), 123-126 (1985-01-19)
14 hypertensive men with type II diabetes sequentially received, in random order, hydrochlorothiazide 50 mg twice a day, propranolol 80 mg twice a day, and both drugs in combination. The 3-week treatment periods were separated by a 1-week washout period.
C Serradeil-Le Gal et al.
The Journal of clinical investigation, 98(12), 2729-2738 (1996-12-15)
SR 121463A, a potent and selective, orally active, nonpeptide vasopressin V2 receptor antagonist, has been characterized in several in vitro and in vivo models. This compound displayed highly competitive and selective affinity for V2 receptors in rat, bovine and human
Michael A Weber et al.
Lancet (London, England), 381(9866), 537-545 (2012-12-12)
In previous clinical trials in high-risk hypertensive patients, paradoxically higher cardiovascular event rates have been reported in patients of normal weight compared with obese individuals. As a prespecified analysis of the Avoiding Cardiovascular Events through Combination Therapy in Patients Living
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持